Prof. Dr. rer.-nat. Thomas Wunderlich

CRC 1607 | Prof. Dr. rer.-nat. Thomas Wunderlich

Max Planck Institute for Metabolism Research
Gleueler Str. 50
50931 Cologne
+49 221 4726 678
Thomas.wunderlich@sf.mpg.de

Projects:

Project leader

Scientific career

2010 Habilitation, Suject: The role of cytokine signaling in the development of obesity and insulin resistance

2005-2007 Institute for Genetics, University of Cologne, Germany

Postdoctoral Fellow, Department of Mouse Genetics and Metabolism, Supervisor: Prof. Dr. Jens C. Brüning

2004 Harvard Medical School, Boston MA, USA, Postdoctoral Fellow CBR Institute for Biomedical Research Inc. Supervisor: Prof. Dr. Klaus Rajewsky

 

Selected publications

  1. Vesting AJ, Jais A, Klemm P, Steuernagel L, Wienand P, Fog-Tonnesen M, Hvid H, Schumacher AL, Kukat C, Nolte H, Georgomanolis T, Altmüller J, Pasparakis M, Schmidt A, Krüger M, Supprian MS, Waisman A, Straub BK, Raschzok N, Bernier M, Birkenfeld AL, Hövelmeyer N, Brüning JC, Wunderlich FT. (2022) NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition. Mol Metab. 2022 Nov 7;66:101626
  2. Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A, Hövelmeyer N, Schäfer SC, Knittel G, Lohneis P, Nikolic M, Wiederstein JL, Franitza M, Georgomonolis T, Reinart N, Herling M, Herling C, Hartmann EM, Rosenwald A, Klapper W, Büttner R, Moia R, Rossi D, Boldorini R, Gaidano G, Frenzel LP, Reinhardt HC, Brüning JC, Hallek M, Krüger M, Peifer M, Pallasch CP, Wunderlich FT. (2021) Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood. 2021 Feb 4;137(5):646-660.
  3. Ostermann, A.L., Wunderlich, C.M., Schneiders, L., Vogt, M.C., Woeste, M.A., Belgardt, B.F., Niessen, C.M., Martiniy, B., Schauss, A.C., Frommolt, P., Nikolaev, A., Hövelmeyer, N., Sears, R.C., Koch, P.J., Günzel, D., Brüning, J.C., Wunderlich, F.T. (2019). Intestinal insulin/IGF1 signalling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer. Nat. Metabol. 1, 371-389.
  4. Mittenbühler, M.J., Sprenger, H.G., Gruber, S., Wunderlich, C.M., Kern, L., Brüning, J.C., Wunderlich, F.T. (2018). Hepatic leptin receptor expression can partially compensate for IL-6Rα deficiency in DEN-induced hepatocellular carcinoma. Mol. Metab. 17, 122-133.
  5. Wunderlich, C.M., Ackermann, P.J., Ostermann, A.L., Adams-Quack, P., Vogt, M.C., Tran, M.L., Nikolajev, A., Waisman, A., Garbers, C., Theurich, S., Mauer, J., Hövelmeyer, N., Wunderlich, F.T. (2018). Obesity exacerbates colitis-associated cancer via IL-6-regulated macrophage polarisation and CCL-20/CCR-6-mediated lymphocyte recruitment. Nat. Commun. 9, 1646.
  6. Timper, K., Denson, J.L., Steculorum, S.M., Heilinger, C., Engström-Ruud, L., Wunderlich, C.M., Rose-John, S., Wunderlich, F.T.*, Brüning, J.C.*. (2017), IL-6 Improves Energy and Glucose Homeostasis in Obesity via Enhanced Central IL-6 trans-Signaling. Cell Rep. 19, 267-280. *equal contributions
  7. Mauer, J., Chaurasia, B., Goldau, J., Vogt, M.C., Ruud, J., Nguyen, K.D., Theurich, S., Hausen, A.C., Schmitz, J., Brönneke, H.S., Estevez, E., Allen, T.L., Mesaros, A., Partridge, L., Febbraio, M.A., Chawla, A., Wunderlich, F.T., Brüning, J.C. (2014). Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat. Immunol. 15, 423-430.